When your levels are low, your body struggles to keep up, and tiredness is usually the first sign
DISSECTION O - ESOC25-604 FIBROMUSCULAR DYSPLASIA AND SPONTANEOUS CERVICAL ARTERY DISSECTION: A SECONDARY ANALYSIS OF THE STOP-CAD STUDY Ahmad Nehme 1 , Liqi Shu 2 , Marion Boulanger 1 , Daniel Mandel 2 , Christopher Leon Guerrero 3 , Esther Kim 3 , Nils Henninger 4 , Bastien Rioux 5 , Aaron Rothstein 6 , Michele Romoli 7 , Setareh Salehi Omran 8 , Marialuisa Zedde 9 , Richa Sharma 10 , Shadi Yaghi 2 , Emmanuel Touz 1 1 Department of Neurology, CHU de Caen-Normandie, Caen, France, 2 Department of Neurology, The Warren Alpert Medical School of Brown University, Brown Medical School, Providence, United States, 3 Sanger Heart and Vascular Institute, Atrium Health, Charlotte, United States, 4 Department of Neurology, University of Massachusetts Chan Medical School, Worcester, United States, 5 Department of Neurosciences, Universit de Montral, Montreal, Canada, 6 Department of Neurology, University of Pennsylvania, Philadelphia, United States, 7 Department of Neurosciences, Bufalini Hospital, Cesena, Italy, 8 Department of Neurology, University of Colorado, Aurora, United States, 9 Neurology Unit, Stroke Unit, Azienda Unit Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy, 10 Department of Neurology, Yale New Haven Hospital, New Haven, United States Background and Aims: Fibromuscular dysplasia (FMD) is found in 6-14% of patients with spontaneous cervical artery dissection (sCeAD)
With the monoclonal antibodies targeting amyloid, we got the first breakthrough. Biogen, the maker of aducanumab, later pulled it from the market to focus on a second drug, which is now one of two such antibodies available in the US
[58] Claims for GH as an anti-aging treatment date back to 1990 when the New England Journal of Medicine published a study wherein GH was used to treat 12 men over 60
Institutional approval was not required
